PolyPid (PYPD) News Today $2.99 -0.01 (-0.33%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$3.00 +0.01 (+0.50%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period PolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D CostsFebruary 13, 2025 | finance.yahoo.comPolyPid targets SHIELD II trial completion with top-line results in Q2 2025February 12, 2025 | msn.comPolyPid (PYPD) Gets a Buy from JMP SecuritiesFebruary 12, 2025 | markets.businessinsider.comPolyPid Ltd. (PYPD) Q4 2024 Earnings Call TranscriptFebruary 12, 2025 | seekingalpha.comPolyPid Updates: New Board Appointment and SHIELD II Trial ProgressFebruary 12, 2025 | tipranks.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsFebruary 12, 2025 | globenewswire.comCraig-Hallum Sticks to Its Buy Rating for PolyPid (PYPD)February 10, 2025 | markets.businessinsider.comPolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 30, 2025 | globenewswire.comPolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025January 29, 2025 | globenewswire.comPolyPid initiated with a Buy at Rodman & RenshawJanuary 29, 2025 | markets.businessinsider.comRodman & Renshaw sets PolyPid stock at Buy with $13 targetJanuary 29, 2025 | msn.comPolyPid files to sell 11.23M ordinary shares for holdersJanuary 22, 2025 | markets.businessinsider.comPolyPid Regains Nasdaq Compliance with Private Placement BoostJanuary 17, 2025 | tipranks.comPolyPid (NASDAQ:PYPD) Stock Quotes, Forecast and News SummaryDecember 26, 2024 | benzinga.comPolyPid price target lowered to $11 from $14 at H.C. WainwrightDecember 26, 2024 | markets.businessinsider.comPolyPid’s SHIELD II Trial Progress and Financial Stability Justify Buy RatingDecember 25, 2024 | markets.businessinsider.comPolyPid announces DSMB recommendation to continue Phase 3 D-PLEX studyDecember 24, 2024 | markets.businessinsider.comPolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 MillionDecember 23, 2024 | globenewswire.comPolyPid’s Strategic Advancements and Clinical Progress: A Buy RecommendationDecember 16, 2024 | markets.businessinsider.comPolyPid announces research, development collaboration with ImmunoGenesisDecember 12, 2024 | markets.businessinsider.comPolyPid (PYPD) Gets a Buy from Craig-HallumDecember 12, 2024 | markets.businessinsider.comPolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer ImmunotherapyDecember 11, 2024 | globenewswire.comPolyPid Ltd.: PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceNovember 30, 2024 | finanznachrichten.dePolyPid receives noncompliance notification from NasdaqNovember 29, 2024 | markets.businessinsider.comPolyPid Faces Nasdaq Non-Compliance ChallengeNovember 29, 2024 | tipranks.comPolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceNovember 29, 2024 | globenewswire.comPolyPid (PYPD) Gets a Hold from BarclaysNovember 19, 2024 | markets.businessinsider.comPositive Indicators and Financial Stability Support Roy Buchanan’s Optimistic Outlook on PolyPid’s StockNovember 16, 2024 | markets.businessinsider.comPolyPid Reports Q3 Results Amid SHIELD II Trial ProgressNovember 15, 2024 | markets.businessinsider.comPolyPid Announces SHIELD II Trial Progress and FinancialsNovember 14, 2024 | markets.businessinsider.comPolyPid Ltd. (PYPD) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comPolyPid (PYPD) Receives a Buy from Craig-HallumNovember 12, 2024 | markets.businessinsider.comPolyPid Announces $8.25 Million Share Sale PlanNovember 9, 2024 | markets.businessinsider.comPolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select ConferenceNovember 7, 2024 | globenewswire.comCraig-Hallum bullish on PolyPid, initiates with a BuyNovember 6, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy RecommendationNovember 6, 2024 | msn.comPolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024October 30, 2024 | globenewswire.comRosalind Advisors, Inc. Reduces Stake in PolyPid LtdOctober 24, 2024 | finance.yahoo.comPolyPid announces publication in IJS on Phase 3 SHIELD I trial of D-PLEX100October 22, 2024 | markets.businessinsider.comPolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal SurgeryOctober 21, 2024 | globenewswire.comPolyPid retains stock target, buy rating on positive trial enrollment updateOctober 4, 2024 | investing.comPolyPid completes enrollment for phase 3 trialOctober 3, 2024 | uk.investing.comBuy Rating Affirmed for PolyPid on D-PLEX’s Positive Trial Milestones and Commercial ProspectsOctober 3, 2024 | markets.businessinsider.comPolyPid Buy Rating Affirmed: Promising Clinical Trials and Solid Financial OutlookOctober 2, 2024 | markets.businessinsider.comPolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsOctober 1, 2024 | globenewswire.comPolyPid to Participate in Three Upcoming Fall Investor ConferencesSeptember 3, 2024 | globenewswire.comPolyPid (PYPD) Receives a Hold from BarclaysAugust 20, 2024 | markets.businessinsider.comPolyPid Ltd (PYPD) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comBuy Rating Affirmed for PolyPid Amidst Strong Trial Progress and Robust Financial PositionAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on D-PLEX Clinical Progress and Potential Early ApprovalAugust 16, 2024 | markets.businessinsider.com Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address PYPD Media Mentions By Week PYPD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYPD News Sentiment▼0.000.60▲Average Medical News Sentiment PYPD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYPD Articles This Week▼01▲PYPD Articles Average Week Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies electroCore News Pro-Dex News Edap Tms News FONAR News TELA Bio News Milestone Scientific News Sensus Healthcare News iCAD News Hyperfine News Lucid Diagnostics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYPD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PYPD Stock Alerts